OraSure Technologies Reports Q3 2026 Revenue Growth Driven by Diagnostics and Sample Management
OraSure Technologies (OSUR) reported third-quarter 2026 revenue of $30.9 million, marking a 14% year-over-year increase. The growth was primarily fueled by a 16% rise in diagnostics revenue—supported by demand for HCV and syphilis testing—and a 21% surge in sample management solutions. While COVID-19 related revenues have effectively collapsed to $22,000, the company's core business remains on an upward trajectory. Despite the revenue growth, the company reported a non-GAAP diluted EPS loss of $0.15 and negative operating cash flow of $10.9 million as it continues to invest in its return-to-growth strategy. Management has pushed back its cash flow breakeven target to the second half of 2027, citing evolving timelines for growth opportunities and the withdrawal of a CT/NG molecular self-test submission.
Tickers: $OSUR
Topics: Diagnostics Revenue Gross Margin Operating Loss Revenue Growth Sample Management Solutions